283 related articles for article (PubMed ID: 34520029)
41. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
42. Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995-2005.
Sheridan J; Manning V; Ridge G; Mayet S; Strang J
Addiction; 2007 Nov; 102(11):1824-30. PubMed ID: 17935587
[TBL] [Abstract][Full Text] [Related]
43. Implementation of a mental health medication management intervention in Australian community pharmacies: Facilitators and challenges.
Hattingh HL; Kelly F; Fowler J; Wheeler AJ
Res Social Adm Pharm; 2017; 13(5):969-979. PubMed ID: 28583302
[TBL] [Abstract][Full Text] [Related]
44. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.
Truong C; Krawczyk N; Dejman M; Marshall-Shah S; Tormohlen K; Agus D; Bass J
Addict Behav; 2019 Jun; 93():14-19. PubMed ID: 30682677
[TBL] [Abstract][Full Text] [Related]
45. Understanding the use of diverted buprenorphine.
Cicero TJ; Ellis MS; Chilcoat HD
Drug Alcohol Depend; 2018 Dec; 193():117-123. PubMed ID: 30359928
[TBL] [Abstract][Full Text] [Related]
46. Demographic and socioeconomic correlates to buprenorphine access in pharmacies.
Welsh JW; Yarbrough CR; Sitar SI; Mataczynski MJ; Peralta AM; Kan M; Crawford ND; Conrad TA; Kee C; Young HN
J Am Pharm Assoc (2003); 2023; 63(3):751-759. PubMed ID: 36658013
[TBL] [Abstract][Full Text] [Related]
47. Adherence to buprenorphine: An analysis of prescription drug monitoring program data.
Pizzicato LN; Hom JK; Sun M; Johnson CC; Viner KM
Drug Alcohol Depend; 2020 Nov; 216():108317. PubMed ID: 33035714
[TBL] [Abstract][Full Text] [Related]
48. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
49. The Howard Street Method: A Community Pharmacy-led Low Dose Overlap Buprenorphine Initiation Protocol for Individuals Using Fentanyl.
Noel M; Abbs E; Suen L; Samuel L; Dobbins S; Geier M; Soran CS
J Addict Med; 2023 Jul-Aug 01; 17(4):e255-e261. PubMed ID: 37579105
[TBL] [Abstract][Full Text] [Related]
50. Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD.
Strickland DM; Baker JT
J Opioid Manag; 2023; 19(7):135-140. PubMed ID: 37879668
[TBL] [Abstract][Full Text] [Related]
51. Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City.
Marotta PL; Abbas BT; Stringer K; Huang D; Schnaidt J; Goddard-Eckrich D; El-Bassel N; Gilbert L
Int J Drug Policy; 2021 Nov; 97():103321. PubMed ID: 34358803
[TBL] [Abstract][Full Text] [Related]
52. The Pregnancy Recovery Center: A women-centered treatment program for pregnant and postpartum women with opioid use disorder.
Krans EE; Bobby S; England M; Gedekoh RH; Chang JC; Maguire B; Genday P; English DH
Addict Behav; 2018 Nov; 86():124-129. PubMed ID: 29884421
[TBL] [Abstract][Full Text] [Related]
53. Federal and State Pharmacy Regulations and Dispensing Barriers to Buprenorphine Access at Retail Pharmacies in the US.
Qato DM; Watanabe JH; Clark KJ
JAMA Health Forum; 2022 Aug; 3(8):e222839. PubMed ID: 36218988
[TBL] [Abstract][Full Text] [Related]
54. I could take the judgment if you could just provide the service: non-prescription syringe purchase experience at Arizona pharmacies, 2018.
Meyerson BE; Lawrence CA; Cope SD; Levin S; Thomas C; Eldridge LA; Coles HB; Vadiei N; Kennedy A
Harm Reduct J; 2019 Sep; 16(1):57. PubMed ID: 31533730
[TBL] [Abstract][Full Text] [Related]
55. Primary Care of Opioid use Disorder: The End of "the French Model"?
Dupouy J; Maumus-Robert S; Mansiaux Y; Pariente A; Lapeyre-Mestre M
Eur Addict Res; 2020; 26(6):346-354. PubMed ID: 32155620
[TBL] [Abstract][Full Text] [Related]
56. Patient Experience and Satisfaction with Opioid-Related Screening and Intervention in North Dakota Community Pharmacies.
Lothspeich E; Werremeyer A; Chase S; Huseth-Zosel A
J Pharm Pract; 2023 Oct; 36(5):1217-1224. PubMed ID: 35704458
[No Abstract] [Full Text] [Related]
57. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
[TBL] [Abstract][Full Text] [Related]
58. Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids.
Chua KP; Brummett CM; Conti RM; Haffajee RL; Prosser LA; Bohnert ASB
JAMA Netw Open; 2019 May; 2(5):e193673. PubMed ID: 31074819
[TBL] [Abstract][Full Text] [Related]
59. The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice.
Varisco TJ; Wanat M; Hill LG; Thornton D
J Am Pharm Assoc (2003); 2023; 63(4):1039-1043. PubMed ID: 37088366
[TBL] [Abstract][Full Text] [Related]
60. Association between opioid analgesic therapy and initiation of buprenorphine management: An analysis of prescription drug monitoring program data.
Alexandridis AA; Dasgupta N; Ringwalt CL; Rosamond WD; Chelminski PR; Marshall SW
PLoS One; 2020; 15(1):e0227350. PubMed ID: 31923197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
